Best Chronic Myeloid Leukemia Podcasts (2024)

1
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs 34:45

2h ago34:45

34:45

In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer. Presenters: Virginia Kaklamani, MD, DSc Prof…

1
Current Clinical Practice and NCCN Guidelines for CLL/SLL 31:33

3h ago31:33

31:33

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among th…

1
RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma 1:00:49

20h ago1:00:49

1:00:49

Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.…

1
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs 28:35

1d ago28:35

28:35

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including: Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the M…

1
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways 24:23

2d ago24:23

24:23

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to…

1
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer 24:30

4d ago24:30

24:30

In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemacicli…

1
Congress to Clinic: Expert Takeaways on Emerging Data for AML 25:21

5d ago25:21

25:21

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractor…

1
Congress to Clinic: Expert Takeaways on Emerging Data for MDS 19:19

8d ago19:19

19:19

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis 1:00:06

11d ago1:00:06

1:00:06

Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis.By Neil Love, MD

1
Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major Conferences 1:16:45

2M ago1:16:45

1:16:45

Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas.By Neil Love, MD

1
Oncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 33:54

2M ago33:54

33:54

Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.By Neil Love, MD

1
Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma 42:08

2M ago42:08

42:08

Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.By Neil Love, MD

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia 1:02:06

2M ago1:02:06

1:02:06

Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.By Neil Love, MD

1
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer 25:55

2M ago25:55

25:55

In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…

1
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 47:23

2M ago47:23

47:23

In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…

1
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series 1:01:09

3M ago1:01:09

1:01:09

Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis.By Neil Love, MD

1
Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal Hemoglobinuria 1:37:16

3M ago1:37:16

1:37:16

Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease.By Neil Love, MD

1
Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences 1:04:36

3M ago1:04:36

1:04:36

Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera.By Neil Love, MD

1
Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences 1:35:11

4M ago1:35:11

1:35:11

Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome.By Neil Love, MD

1
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer 48:15

4M ago48:15

48:15

In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomiz…

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma 1:00:13

4M ago1:00:13

1:00:13

Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma.By Neil Love, MD

1
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer 36:29

4M ago36:29

36:29

In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including: Challenges with the pathologic testing for HER2-low expression Optimal treatmen…

1
Acute Myeloid Leukemia, Part II

5M ago

—

Leukemia is a medical term for cancer of the blood cells. Acute Myeloid Leukemia, known as AML is the most common acute leukemia in adults. AML is rapidly lethal if untreated, but overall survival has improved for those under age 65 from just 8 months in the late 1970s to 46 months in 2014. We’ll have […]…

1
Acute Myeloid Leukemia, Part I

5M ago

—

Leukemia is a medical term for cancer of the blood cells. Acute Myeloid Leukemia, known as AML is the most common acute leukemia in adults. AML is rapidly lethal if untreated, but overall survival has improved for those under age 65 from just 8 months in the late 1970s to 46 months in 2014. We’ll have […]…

1
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series 1:00:12

5M ago1:00:12

1:00:12

Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis.By Research To Practice

1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia 58:01

5M ago58:01

58:01

Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia.By Neil Love, MD

1
Multiple Myeloma in Underrepresented Populations: Treatment Considerations 24:04

6M ago24:04

24:04

Dr. Azam Farooqui (@azamfarooqui ) and Dr. Monique Hartley-Brown (@DrMHB1) discuss therapeutic considerations regarding current and emerging agents for patients with multiple myeloma from underrepresented racial and ethnic groups. Coming Soon! Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! P…

1
Multiple Myeloma in Underrepresented Populations: Survival Outcomes 18:54

6M ago18:54

18:54

Dr. Azam Farooqui (@azamfarooqui )and Dr. Sikander Ailawadhi answer the question: Why do we need earlier diagnosis and intervention in patients with multiple myeloma from underrepresented racial and ethnic groups? Coming Soon! Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will …

1
Multiple Myeloma in Underrepresented Populations: Clinical Risk 16:42

6M ago16:42

16:42

Dr. Azam Farooqui (@azamfarooqui) and Dr. Urvi Shah (@UrviShahMD) identify factors that impact outcomes for patients with multiple myeloma from underrepresented racial and ethnic groups. Coming Soon! Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased abilit…

1
IMPACT II: Impacting Multiple Myeloma in All CommuniTies 1:33

6M ago1:33

1:33

Season 2: IMPACT II: Impacting Multiple Myeloma in All CommuniTies Unlock insights into the treatment of multiple myeloma within underrepresented racial and ethnic populations with this series of three enlightening podcast episodes. Join experts from both academic and community oncology settings as they dive into critical aspects of clinical risk, …

1
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part Series 1:00:25

6M ago1:00:25

1:00:25

Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.By Neil Love, MD

1
Multimodal Analgesia for Acute Pain and Seglentis™: Part II

7M ago

—

When we experience pain, it begins as an acute process. It might be an ankle sprain, arm fracture, or due to surgery. In fact, chronic postsurgical pain affects up to 50% of adults. Guidelines suggest using multimodal analgesia to manage acute pain. Seglentis, a unique oral medication is available that combines tramadol, a weak opioid […]…

1
Multimodal Analgesia for Acute Pain and Seglentis™: Part I

7M ago

—

When we experience pain, it begins as an acute process. It might be an ankle sprain, arm fracture, or due to surgery. In fact, chronic postsurgical pain affects up to 50% of adults. Guidelines suggest using multimodal analgesia to manage acute pain. Seglentis, a unique oral medication is available that combines tramadol, a weak opioid […]…

1
Current Considerations for Adverse Event Management With HER3-Directed Agents 12:33

7M ago12:33

12:33

The third and final episode in a 3-part series covers the safety profile of and considerations for managing adverse events associated with HER3-targeted antibody–drug conjugates, including patritumab deruxtecan (HER3-DXd) and others, in the setting of lung cancer. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of M…

1
Unpacking the Potential of HER3-Targeted Therapy in NSCLC 15:24

7M ago15:24

15:24

This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including: Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab The HER2xHER3 bispecific antibody zenocutuzumab The HER3-targeted anti…

1
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer 8:54

7M ago8:54

8:54

This first episode in a 3-part series tackles the role of HER3 in cancer, specifically in NSCLC, and how HER3 can be effectively targeted with ADCs. Presenters in this series include: Rebecca S. Heist, MD, MPH Associate Professor of Medicine Harvard Medical School Medical Oncology Massachusetts General Hospital Boston, Massachusetts Helena Yu, MD A…

1
Expert Insight on Seminal New Clinical Trial Data Presented at the 2023 IGCS Conference Informing Treatment for Endometrial, Ovarian, and Cervical Cancers 30:29

8M ago30:29

30:29

In this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including: Phase III NRG GY018 trial of carboplatin and paclitaxel with or without pembrolizumab followed by pembrolizumab or plac…

1
Novel Emerging Investigational Treatment Strategies for Patients With Myelofibrosis 19:33

8M ago19:33

19:33

In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including: Navitoclax (BCL-XL/BCL-2 inhibitor) Pelabresib (BET inhibitor) Imetelstat (telomerase inhibitor) Luspatercept (erythroid maturation agent) Additional strategies Presenter: Jacqueline S. …

1
A Year in Review and a Look to the Future: BTKi in CLL and MCL 27:33

8M ago27:33

27:33

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: SHINE: First-Line Ibrutinib + Bendam…

1
Expert Insight on Key Updates and New Clinical Trial Data From the ESMO 2023 Congress Informing Treatment for Endometrial, Ovarian, and Cervical Cancers 33:18

8M ago33:18

33:18

In this episode, Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, provide expert insights on new clinical trial data presented at the 2023 ESMO annual congress for endometrial, ovarian, and cervical cancers, including: Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclit…

1
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part Series 1:01:30

9M ago1:01:30

1:01:30

Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes.By Neil Love, MD

1
Expert Insights and Considerations for Precision Care With HER3-Targeted Agents in NSCLC and Breast Cancer 38:51

8M ago38:51

38:51

In this episode, Aakash Desai, MD; Narjust Florez, MD; and Paolo Tarantino, MD, discuss the biologic rationale and clinical development of agents targeting HER3 for the treatment of breast and lung cancers. The potential niche for HER3-targeted agents in these treatment landscapes is considered, with consideration of acquired resistance to previous…

1
Improving Care for Black Patients With Endometrial Cancer 26:58

9M ago26:58

26:58

In this episode, Dr Leslie Boyd and Adrienne Moore, a patient advocate and endometrial cancer survivor, discuss how healthcare professionals can partner with Black patients to improve the diagnosis and management of endometrial cancer (EC). Topics include: Data on racial disparities in EC survival Importance of listening to Black patients to better…

1
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part Series 1:01:44

9M ago1:01:44

1:01:44

Dr Naval Daver from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses current and emerging optimal management approaches for patients with acute myeloid leukemia and myelodysplastic syndromes.By Neil Love, MD

1
What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma 1:01:33

9M ago1:01:33

1:01:33

Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.By Neil Love, MD

1
Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences 1:19:48

9M ago1:19:48

1:19:48

Dr Joseph Mikhael from the City of Hope Cancer Center in Phoenix, Arizona, discusses recent updates and future directions in the management of newly diagnosed and relapsed/refractory multiple myeloma.By Neil Love, MD

Podcasts Worth a Listen

Chronic Myeloid Leukemia Podcasts

Podcasts Worth a Listen

Quick Reference Guide